As a result of the agreement, MammaTyper^® will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.

MammaTyper^® is the first real innovation in subtyping breast cancer in decades. Using RT-qPCR technology proven during the COVID-19 pandemic, the multigene test works through an easily replicated and quantitative measurement of marker gene expression, classifying each sample as a St. Gallen molecular subtype. MammaTyper^® provides standardised, objective results and can also accurately assess HER2-low tumours and Ki-67 markers, offering a reliable basis for selecting the best treatment option for patients.

By being robustly reproducible, it avoids many of the common pre-analytical errors in the pathology laboratory, especially for the proliferation marker Ki-67 – critical in luminal subtyping and prognosis. Using MammaTyper® to subtype breast cancer tissue is a valuable resource for pathologists and can provide the reassurance with accurate subtyping for tailored treatment which are patient-specific.

By sharing deep scientific knowledge and an understanding of clinical needs, Sysmex Life Science and Cerca Biotech will work closely together to enable individualised breast cancer diagnostics across many markets.

Richard Hughes, Director at Cerca Biotech: 

“Repeatable, reproducible testing is the only way we can ensure that every person diagnosed with breast cancer can access the best treatment for their individual case. Through this partnership with Sysmex Europe, MammaTyper^® will be available as a valuable diagnostic tool to more pathologists in more markets across Europe. We are proud that MammaTyper^®will be part of Sysmex’s cutting-edge portfolio.”

Samantha Giangregorio, Head of Life Science, Vice President Sysmex Europe SE: 

“We are excited to be collaborating with Cerca Biotech and to extend and strengthen our innovative molecular portfolio, building on the success of our OSNA^® solution in breast cancer. Considering the clinical need for accurate and individualised diagnostics, the MammaTyper^® can play a key role in the breast cancer diagnostic pathway, providing guidance for the right treatment, thus improving the quality of life of patients.”

For more information, visit www.sysmex-europe.com.

MammaTyper kits